Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss
Abstract Background/Aims It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion. Methods Patients w...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-025-02700-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688100686528512 |
|---|---|
| author | Na Gao Haishi Wu Bin Li Huiying Yu Lili Wu Jing Zhang Nan Zhang Bingliang Lin Qiyi Zhao Zhiliang Gao |
| author_facet | Na Gao Haishi Wu Bin Li Huiying Yu Lili Wu Jing Zhang Nan Zhang Bingliang Lin Qiyi Zhao Zhiliang Gao |
| author_sort | Na Gao |
| collection | DOAJ |
| description | Abstract Background/Aims It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion. Methods Patients who experienced serum HBsAg loss after PEG-IFN-based therapy were enrolled and followed up for 96 weeks. Propensity score matching (PSM) was performed using a 1:1 ratio to adjust for the associated factors. A multivariate logistic regression analysis was used to determine the factors associated with HBsAg seroreversion. Results In total, 220 patients with HBsAg seroclearance were divided into NUCs (n = 54) and non-NUCs (n = 166) consolidation therapy groups. At week 96, the HBsAg seroreversion (12/54 vs. 31/166, P = 0.709) and virological relapse (2/54 vs. 10/166, P = 0.759) rates were similar in the NUCs and non-NUCs groups. After PSM, HBsAg seroreversion (12/53 vs. 13/53; P = 1.000) and virological relapse (2/53 vs. 4/53; P = 0.674) rates were not significantly different between the two groups. Serum hepatitis B surface antibody titer (odds ratio, 0.388; 95% confidence interval, 0.245–0.616; P < 0.001) was found to be associated with HBsAg seroreversion, while NUCs continuation was not related to HBsAg seroreversion. Conclusions NUCs continuation is not associated with a lower risk of HBsAg seroreversion in patients with serum HBsAg loss following PEG-IFN-based therapy. |
| format | Article |
| id | doaj-art-8f667c495ae84e56a0e1b8edbe5d3a0a |
| institution | DOAJ |
| issn | 1743-422X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj-art-8f667c495ae84e56a0e1b8edbe5d3a0a2025-08-20T03:22:08ZengBMCVirology Journal1743-422X2025-03-012211910.1186/s12985-025-02700-2Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg lossNa Gao0Haishi Wu1Bin Li2Huiying Yu3Lili Wu4Jing Zhang5Nan Zhang6Bingliang Lin7Qiyi Zhao8Zhiliang Gao9Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen UniversityAbstract Background/Aims It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion. Methods Patients who experienced serum HBsAg loss after PEG-IFN-based therapy were enrolled and followed up for 96 weeks. Propensity score matching (PSM) was performed using a 1:1 ratio to adjust for the associated factors. A multivariate logistic regression analysis was used to determine the factors associated with HBsAg seroreversion. Results In total, 220 patients with HBsAg seroclearance were divided into NUCs (n = 54) and non-NUCs (n = 166) consolidation therapy groups. At week 96, the HBsAg seroreversion (12/54 vs. 31/166, P = 0.709) and virological relapse (2/54 vs. 10/166, P = 0.759) rates were similar in the NUCs and non-NUCs groups. After PSM, HBsAg seroreversion (12/53 vs. 13/53; P = 1.000) and virological relapse (2/53 vs. 4/53; P = 0.674) rates were not significantly different between the two groups. Serum hepatitis B surface antibody titer (odds ratio, 0.388; 95% confidence interval, 0.245–0.616; P < 0.001) was found to be associated with HBsAg seroreversion, while NUCs continuation was not related to HBsAg seroreversion. Conclusions NUCs continuation is not associated with a lower risk of HBsAg seroreversion in patients with serum HBsAg loss following PEG-IFN-based therapy.https://doi.org/10.1186/s12985-025-02700-2Chronic hepatitis BNucleos(t)ide analogsSeroreversionFunctional cure |
| spellingShingle | Na Gao Haishi Wu Bin Li Huiying Yu Lili Wu Jing Zhang Nan Zhang Bingliang Lin Qiyi Zhao Zhiliang Gao Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss Virology Journal Chronic hepatitis B Nucleos(t)ide analogs Seroreversion Functional cure |
| title | Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss |
| title_full | Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss |
| title_fullStr | Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss |
| title_full_unstemmed | Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss |
| title_short | Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss |
| title_sort | nucleos t ide analogs continuation is not associated with a lower risk of hbsag seroreversion following peg ifn induced hbsag loss |
| topic | Chronic hepatitis B Nucleos(t)ide analogs Seroreversion Functional cure |
| url | https://doi.org/10.1186/s12985-025-02700-2 |
| work_keys_str_mv | AT nagao nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT haishiwu nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT binli nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT huiyingyu nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT liliwu nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT jingzhang nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT nanzhang nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT binglianglin nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT qiyizhao nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss AT zhilianggao nucleostideanalogscontinuationisnotassociatedwithalowerriskofhbsagseroreversionfollowingpegifninducedhbsagloss |